Two recent studies by Deininger et al. (2016) and Hernandez et al. (2024) examined the influence of CYP3A genetic polymorphisms, particularly in CYP3A5 and CYP3A4, on tacrolimus pharmacokinetics in adult heart transplant recipients [21,22]. This evidence concerns the gene CYP3A5 and cardiac transplant.